Kathryn Bellin
Primary Care · Lake Odessa, MINPI 1962028258
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 223 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 30.5% of the total. Reporting peaked in 2023 at $1,193 and has fallen 53.1% since, to $560 in 2025. Among primary care clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 223 payments — averaging $20.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$936
- AstraZeneca$403
- Supernus Pharmaceuticals, Inc.$252
- Xeris Pharmaceuticals, Inc.$211
- Esperion Therapeutics, Inc.$169
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,581100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 83 | $1,396 |
| Novo Nordisk | 32 | $936 |
| AstraZeneca | 15 | $403 |
| Supernus Pharmaceuticals, Inc. | 15 | $252 |
| Xeris Pharmaceuticals, Inc. | 6 | $211 |
| Esperion Therapeutics, Inc. | 4 | $169 |
| Lilly USA, LLC | 9 | $160 |
| GSK | 8 | $140 |
| Pfizer | 7 | $129 |
| Novartis | 5 | $103 |
| Amgen | 5 | $102 |
| E.r. Squibb & Sons, L.L.C. | 6 | $95 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $69 |
| Johnson & Johnson | 4 | $66 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $60 |
| Exact Sciences | 3 | $56 |
| Eisai Inc. | 2 | $46 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Corcept Therapeutics | 1 | $21 |
| Astellas Pharma US Inc | 1 | $19 |
| Mannkind Corporation | 1 | $17 |
| Antares Pharma, Inc. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Verona Pharma, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $13 |
| Tandem Diabetes Care, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,581 in reported general payments places this provider in the 90th percentile of 292 primary care providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 35 | $35,134 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $20,690 |
| EliquisApixaban | 25 | $18,334 |
| XareltoRivaroxaban | 23 | $14,653 |
| MyrbetriqMirabegron | 13 | $6,725 |
| Rosuvastatin Calcium | 109 | $2,071 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 21 | $1,428 |
| Atorvastatin Calcium | 72 | $975 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $854 |
| Lisinopril | 79 | $741 |
| Omeprazole | 45 | $659 |
| Duloxetine Hcl | 17 | $550 |
| Levothyroxine Sodium | 28 | $513 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 15 | $500 |
| Fluoxetine Hcl | 24 | $495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $160 | $35,13435 claims |
| GSKTrelegy Ellipta | $140 | $20,69024 claims |
| PfizerEliquis | $129 | $18,33425 claims |
| Johnson & JohnsonXarelto | $66 | $14,65323 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $6,72513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 292 primary care providers in Michigan.
Other primary care in Lake Odessa
- Donna HamillGrosse Pointe$17K
- Marie Sighe-NzokouLansing$16K
- Alexandria SchwabBay City$10K
- Amy HenryRochester Hills$10K
- Claire GebaraWaterford$9K
- Vanita RobinsonDetroit$9K
- Mary BoudreauMason$9K
- Kimberly FrazierLansing$8K
- Rachel HetznerMadison Heights$8K
- Katherine HouleMarquette$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.